Drugs.com - FDA MedWatch Alerts

FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy

Audience: Patient, Health Care Professional, Pharmacy, Immunology, Pulmonology ISSUE: FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc...

Feb 9, 2025 - 21:44
 0
FDA Requires Guillain-Barré Syndrome (GBS) Warning in the Prescribing Information for RSV Vaccines Abrysvo and Arexvy
Audience: Patient, Health Care Professional, Pharmacy, Immunology, Pulmonology ISSUE: FDA has required and approved safety labeling changes to the Prescribing Information for Abrysvo (Respiratory Syncytial Virus Vaccine) manufactured by Pfizer Inc...
Read More

Tags:

Previous Article

FDA Warns Health Care Professionals Not to Use Epinephrine Nasal Solutions from ...

Next Article

Astellas Issues Recall of One Lot of Prograf 0.5 mg and One Lot of Astagraf XL 0...

Related Posts

Drug Safety Communication: Copaxone, Glatopa (glatiramer acetate) - FDA Adds Boxed Warning About a Rare but Serious Allergic Reaction Called Anaphylaxis

Drug Safety Communication: Copaxone, Glatopa (glatirame...

Feb 9, 2025  0

Shoppers-Plaza Issues Voluntary Nationwide Recall of Fouzee Sugarlin Herbal Formula Due To Presence Of Undeclared Metformin And Glyburide

Shoppers-Plaza Issues Voluntary Nationwide Recall of Fo...

Feb 9, 2025  0

One Source Nutrition, Inc. Issues Voluntary Nationwide Recall of Vitality Capsules Due to Presence of Undeclared Sildenafil and Tadalafil

One Source Nutrition, Inc. Issues Voluntary Nationwide ...

Feb 23, 2025  0